Len W Seymour

List of Publications by Year
in descending order

70 papers	4,299 citations	147566 31 h-index	118652 62 g-index
71 all docs	71 docs citations	71 times ranked	5211 citing authors

#	Article	IF	Citations
1	Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination. Nature Communications, 2022, 13, 1182.	5.8	13
2	Optogenetically Engineered Neurons Differentiated from Human SH-SY5Y Cells Survived and Expressed ChR2 in 3D Hydrogel. Biomedicines, 2022, 10, 1534.	1.4	0
3	Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers, 2021, 13, 719.	1.7	6
4	Promises and challenges of adoptive T-cell therapies for solid tumours. British Journal of Cancer, 2021, 124, 1759-1776.	2.9	113
5	Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. , 2021, 9, e001292.		34
6	Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes and Development, 2021, 35, 602-618.	2.7	61
7	Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Molecular Therapy, 2021, 29, 1668-1682.	3.7	33
8	Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Molecular Therapy - Oncolytics, 2021, 21, 47-61.	2.0	8
9	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
10	A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response. European Journal of Pharmaceutical Sciences, 2020, 152, 105456.	1.9	16
11	Development of a novel mammalian display system for selection of antibodies against membrane proteins. Journal of Biological Chemistry, 2020, 295, 18436-18448.	1.6	12
12	The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 115-123.	3.2	5
13	Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response. Cancers, 2020, 12, 3827.	1.7	12
14	Peptideâ€"TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nature Biotechnology, 2020, 38, 320-332.	9.4	210
15	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers, 2020, 12, 798.	1.7	11
16	Attenuation of the Hypoxia Inducible Factor Pathway after Oncolytic Adenovirus Infection Coincides with Decreased Vessel Perfusion. Cancers, 2020, 12, 851.	1.7	9
17	Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity. Methods in Molecular Biology, 2020, 2058, 261-270.	0.4	5
18	Calcium Influx Caused by ER Stress Inducers Enhances Oncolytic Adenovirus Enadenotucirev Replication and Killing through PKCÎ± Activation. Molecular Therapy - Oncolytics, 2019, 15, 117-130.	2.0	7

#	Article	IF	Citations
19	Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity <i>In Vitro</i> and <i>In Vivo</i>. Bioconjugate Chemistry, 2019, 30, 1244-1257.	1.8	17
20	Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. , 2019, 7, 320.		58
21	Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference. Cancer Gene Therapy, 2019, 26, 59-73.	2.2	17
22	Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction. Biomacromolecules, 2019, 20, 854-870.	2.6	32
23	Optogenetic control of iPS cellâ€derived neurons in 2D and 3D culture systems using channelrhodopsinâ€2 expression driven by the synapsinâ€1 and calciumâ€calmodulin kinase II promoters. Journal of Tissue Engineering and Regenerative Medicine, 2019, 13, 369-384.	1.3	22
24	Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells. Cancer Research, 2019, 79, 331-345.	0.4	27
25	Solid Tumor Immunotherapy with T Cell Engagerâ€Armed Oncolytic Viruses. Macromolecular Bioscience, 2018, 18, 1700187.	2.1	56
26	An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. Cancer Research, 2018, 78, 6852-6865.	0.4	123
27	Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirusÂin murine cancer cells. , 2018, 6, 55.		16
28	Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Molecular Therapy - Oncolytics, 2017, 4, 18-30.	2.0	37
29	OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Molecular Therapy - Oncolytics, 2017, 4, 55-66.	2.0	17
30	Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology, 2017, 505, 162-171.	1.1	16
31	Oncolytic adenovirus expressing bispecific antibody targets Tâ€cell cytotoxicity in cancer biopsies. EMBO Molecular Medicine, 2017, 9, 1067-1087.	3.3	104
32	Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy - Oncolytics, 2017, 5, 62-74.	2.0	40
33	Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Human Gene Therapy, 2017, 28, 1033-1046.	1.4	14
34	Combining Oncolytic Adenovirus with Radiationâ€”A Paradigm for the Future of Radiosensitization. Frontiers in Oncology, 2017, 7, 153.	1.3	32
35	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
36	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. Bioconjugate Chemistry, 2016, 27, 2372-2385.	1.8	44

#	Article	IF	Citations
37	Oncolytic viruses: finally delivering. British Journal of Cancer, 2016, 114, 357-361.	2.9	95
38	A PTENtial cause for the selectivity of oncolytic viruses?. Nature Immunology, 2016, 17, 225-226.	7.0	8
39	Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses. Molecular Therapy, 2016, 24, 204-205.	3.7	4
40	Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth. Molecular Therapy, 2016, 24, 796-804.	3.7	29
41	Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction. Journal of Cell Science, 2016, 129, 108-120.	1.2	8
42	A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation. PLoS ONE, 2016, 11, e0166383.	1.1	12
43	Improved <i>In Vitro</i> Human Tumor Models for Cancer Gene Therapy. Human Gene Therapy, 2015, 26, 249-256.	1.4	6
44	Macrophages and their interactions with oncolytic viruses. Current Opinion in Pharmacology, 2015, 24, 23-29.	1.7	10
45	In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nature Biotechnology, 2015, 33, 1201-1210.	9.4	362
46	Non-invasive and real-time passive acoustic mapping of ultrasound-mediated drug delivery. Physics in Medicine and Biology, 2014, 59, 4861-4877.	1.6	75
47	Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet, The, 2014, 383, 1129-1137.	6.3	689
48	Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes. Journal of Controlled Release, 2014, 178, 101-107.	4.8	73
49	Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound. Journal of Controlled Release, 2013, 169, 40-47.	4.8	56
50	Enhanced Tumor Uptake and Penetration of Virotherapy Using Polymer Stealthing and Focused Ultrasound. Journal of the National Cancer Institute, 2013, 105, 1701-1710.	3.0	98
51	Targeting of Liposomes via PSGL1 for Enhanced Tumor Accumulation. Pharmaceutical Research, 2013, 30, 352-361.	1.7	9
52	Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine, 2012, 7, 1683-1695.	1.7	23
53	Ultrasound-enhanced drug delivery for cancer. Expert Opinion on Drug Delivery, 2012, 9, 1525-1538.	2.4	100
54	Virotherapy â€“ cancer targeted pharmacology. Drug Discovery Today, 2012, 17, 215-220.	3.2	13

#	Article	IF	Citations
55	Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model. Journal of Controlled Release, 2012, 157, 235-242.	4.8	75
56	Cavitation-Enhanced Extravasation for Drug Delivery. Ultrasound in Medicine and Biology, 2011, 37, 1838-1852.	0.7	106
57	Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release, 2011, 150, 196-203.	4.8	29
58	Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. Journal of Controlled Release, 2011, 156, 381-389.	4.8	49
59	Oncolytic Virotherapy: Combining First-Rate Science with an Unmet Clinical Need. Human Gene Therapy, 2011, 22, 387-388.	1.4	0
60	Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelialâ€"epithelial Syncytia. Molecular Therapy, 2011, 19, 67-75.	3.7	16
61	Adenovirus: Teaching an Old Dog New Tricks. Human Gene Therapy, 2011, 22, 1041-1042.	1.4	6
62	HPMA copolymers for masking and retargeting of therapeutic virusesâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 240-245.	6.6	78
63	Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells. PLoS Pathogens, 2009, 5, e1000440.	2.1	115
64	Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. Journal of Controlled Release, 2009, 135, 152-158.	4.8	52
65	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	0.6	183
66	Retargeting polymerâ€coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine, 2008, 10, 280-289.	1.4	52
67	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy, 2008, 16, 244-251.	3.7	81
68	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE, 2008, 3, e2409.	1.1	158
69	Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. Journal of Drug Targeting, 2007, 15, 546-551.	2.1	45
70	Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. Molecular Therapy, 2006, 14, 118-128.	3.7	138